The 15 billion contrast agent market welcomes new players again!

According to data from Menet.

The 15 billion contrast agent market is making waves again! 3 products have been approved this year

Sales of terminal contrast agents in public medical institutions in China in recent years (unit: 100 million yuan)

Source: Mi Nei.

A few days ago, the 2021 national medical insurance drug catalog adjustment that has received much attention has come to an end.

From the perspective of manufacturers, Jiangsu Hengrui Pharmaceutical, General Electric, Yangtze River Pharmaceutical Group, Bayer, and Bracco are in the top five, with a total market share of more than 80%; Nanjing Zhengda Tianqing Pharmaceutical has a strong growth rate of more than 200% Rising to the eighth place, it is the fastest growing manufacturer in the TOP10

Contrast agent products approved for marketing since 2021

Source: Meinenet MED2.

Since the beginning of this year, three contrast agents have been approved for the market, namely Nanjing Hairong Pharmaceutical|Nanjing Hairong Pharmaceutical Technology’s Ruijia Nuosheng Injection, Shandong Kelun Pharmaceutical’s Iopamidol Injection, and Hunan Kelun Pharmaceutical’s Disodium Gadolinium Injection

Reganosant injection is the world's first selective adenosine A2a receptor agonist.

Iopamidol nonionic monomers Italy Bracco contrast agents developed for neuroradiological related, angiography, digital subtraction angiography, urography, CT scanning enhanced examination

TOP10 products have surged across the board, with sales of three major products exceeding 1 billion

2021H1 TOP10 Terminal Contrast Agent Products in Public Medical Institutions in China

Source: Mi Nei.

Among the TOP10 products, the sales of 3 products exceeded 1 billion yuan

From the perspective of growth rate, 10 products have exceeded double-digit growth.

2021H1 China's top 10 public medical institutions' terminal contrast media brands

Source: Mi Nei.

Among the TOP10 brands, the sales of 2 brands exceeded 1 billion yuan

In terms of growth rate, Nanjing Chia Tai Tianqing Pharmaceutical's iodixanol injection is the fastest, with sales soaring from more than 20 million yuan in 2019 to more than 200 million yuan in 2020, and a year-on-year growth of 194.

13 contrast agents are under review! Yangtze River, Kelun, Beite.

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Up to now, 7 contrast media products have been evaluated by enterprises, among which, iohexol injection and iodixanol injection have been included in the fifth batch of centralized procurement, iopamidol injection and gadolinium disodium injection The competition conditions of 3 or more companies have been met (3 companies have reviewed or 2 companies have reviewed +1 original research)
.

In addition, there are three supplementary applications for consistency evaluation of products under review and approval, namely, Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical’s Iohexol Injection, Jiangsu Hengrui Pharmaceutical’s Gadoterate Meglumine Injection, and Beijing Beilu Pharmaceutical's iopamidol injection
.

Contrast media delivery status under review since 2018

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

Since 2018, a total of 13 contrast agents have been reported for production and are under review and approval.
Among them, gadobutrol injection is the most popular, with 4 companies; iopamidol injection, gadoterate meglumine injection, and poppy iodide injection There are 2 companies applying for production of 5 products including liquid
.
In addition, iopromide injection, gadobutrol injection, gadobutrol injection and other domestic generic pharmaceutical companies have not been approved, involving Jiangsu Hengrui Pharmaceutical, Chengdu Better Pharmaceutical, Hunan Kelun Pharmaceutical, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceutical and many other companies
.

Source: Minet.
com database, company announcement

Statistics are as of December 6, if there are any omissions, please correct me!